Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer


CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about the potential use of gabapentin (Neurontin) in head and neck cancer following negative results in a population of patients with oropharynx cancer. Cook emphasized that although gabapentin did not appear particularly useful in the study’s population, it could have use in a post-surgical population of patients with head and neck cancer who are undergoing radiotherapy.


Negative findings are an important part of reporting findings in medicine. The role of gabapentin is still debated in its utilization for patients with head and neck cancer. The results from other studies have been mixed, [as to] whether it’s helpful or not. Our study was a little bit different than others. We used a very select group of patients with locally advanced oropharynx cancer [receiving] concurrent chemoradiotherapy. Given that we had negative findings regarding this patient population, we think that it’s unlikely that gabapentin is beneficial for this group of [patients. As] these negative results that can inform future studies, [we may how] resources should be directed in other ways.

Gabapentin may not be the most useful thing to study in the future, and there can be other strategies that can be looked at. I know right now in head and neck cancers, especially human papillomavirus–positive oropharynx cancer, treatment de-escalation or deintensification is a hot topic right now. That is something worthwhile that should be pursued; maybe different medications if people have ideas about that. It’s beneficial in terms of guiding future studies and future efforts from that standpoint. Also, again, it’s a very select group of patients, so I don’t think these results can be generalized to the entire head and neck cancer patient population. I think that gabapentin may still be beneficial for patients who’ve maybe undergone surgery and are getting radiation after or possibly different subsites. For this group, it seems to not [have worked].


Cook AE, Modh A, Ali H, et al. Randomized phase III, double-blind, placebo-controlled study of prophylactic gabapentin for the reduction of radiation therapy-induced pain during the treatment of oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2021; 111 (suppl 3): S61-S62. doi/10.1016/j.ijrobp.2021.07.156

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content